
|Videos|August 9, 2022
Factors for Consideration when Choosing an ADT Regimen for mCSPC
Author(s)Jason Hafron, MD
Jason Hafron, MD, revisits the patient profile and discusses factors that inform treatment decision-making in mCSPC.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
2
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
3
Daniel George, MD, on the significance of the capivasertib approval for PTEN-deficient prostate cancer
4
EV plus pembro approval reframes first conversation in MIBC diagnosis
5














